Mira Pharmaceuticals, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
MIRA Pharmaceuticals, Inc. has issued a proxy statement detailing its upcoming virtual Annual Meeting of Shareholders on September 11, 2026, where key proposals including director elections and auditor ratification will be addressed.
NASDAQ
MIRA Pharmaceuticals seeks stockholder approval for a merger with SKNY Pharmaceuticals, creating a biopharma company focused on novel therapeutics for smoking cessation, obesity, pain, and cognitive impairment.
NASDAQ
MIRA Pharmaceuticals, Inc. has filed a Definitive Proxy Statement with the SEC.
NASDAQ
MIRA Pharmaceuticals, Inc. files a definitive proxy statement with the SEC.
NASDAQ
MIRA Pharmaceuticals is holding its annual meeting of stockholders on September 12, 2024, to vote on the election of directors, ratification of the auditor, amendments to the 2022 Omnibus Incentive Plan, and adjournment if necessary.